Squarepoint
ELVN icon

Squarepoint’s Enliven Therapeutics ELVN Stock Holding History

Squarepoint’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Buy
+5,099
New +$216K ﹤0.01% 3918
2026
Q1 		– Sell
-20,763
Closed -$320K – 4432
2025
Q4 		$320K Sell
20,763
-15,082
-42% -$300K ﹤0.01% 3554
2025
Q3 		$734K Buy
+35,845
New +$723K ﹤0.01% 2915

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Squarepoint's ELVN Position: Q2 2026 in Review

Squarepoint opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 5,099 shares worth $259K. The stake represents ﹤0.01% of the portfolio and ranks #3918 among its holdings. This is a return to the name: Squarepoint previously reported a position in ELVN as recently as Q4 2025.

Squarepoint first reported a position in ELVN in Q3 2025 and has held it in 3 quarters since. The position peaked at $734K in Q3 2025. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Squarepoint held 5,099 shares of Enliven Therapeutics worth $259K as of Q2 2026.
  • Enliven Therapeutics was a new Squarepoint position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3918 holding.
  • Squarepoint first reported a position in Enliven Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Squarepoint's Enliven Therapeutics position peaked at $734K in Q3 2025.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.